By Dr. David A. Jernigan
A novel treatment called, Induced Native Phage Therapy (INPT) has been used to target dozens of types of microbes in 280 chronically ill people, with never before seen results. Of these 280 people, there have been 60 blood tests performed on almost 30 people with previously diagnosed, non-responsive Borrelia spirochete infections. A before and after Phelix Borrelia-Phage test was used to first document that they did indeed have the borrelia still, and after two weeks of INPT treatment, a repeat test was performed which showed that 100% of the people were negative for any residual Borrelia. Clinical improvements were often above expectations, while others suffered from years of damage to their tissues as a result of the many failed treatments and the illness itself. Of the 280 people, there were none to mild worsening of symptoms, in spite of the speed of Borrelia elimination. The reason for the rapid elimination and minimal “herx” reactions is explained in this article. INPT appears to able to target Borrelia and eliminate it within two weeks, without toxic and potentially harmful effects, which are common with all antibiotics, as documented by the newest and most sensitive Borrelia testing, the Phelix Borrelia-Phage Test.
Treatment-resistant, chronic and apparent relapsing Lyme disease (borreliosis), with its oft associated co-infections which worsen the illness, though once debated, is now well-documented in the scientific literature. Chronic Lyme disease has reached the true status of a global pandemic, though largely unappreciated by the media and mainstream medicine. The politics of medical policy bias prevails in many if not most mainstream medical schools and associations. Due to the prevalence of medical bias against the recognition of the common occurrence of chronic and persistent nature of Lyme disease, the development of out-of-the-box thinking in the treatment has been limited to trial and error, often resulting in increased improvements, as well as increased suffering caused by varied and long-term antibiotics by more forward thinking physicians. The desperation of those suffering from Lyme Disease leads many to rush to the next newest antibiotic in a Russian-Roulette of risking being one of the many people whose symptoms worsen instead of improve with the latest antibiotic, such as Disulfiram, which helps some people, yet harms others.
As stated by Kenneth Liegner, MD in his journal article on the use of Disulfiram for the treatment of Lyme Disease, reporting on the successful treatment of three patients using Disulfiram, “The persistence of borrelial and piroplasm infections despite treatment poses a dilemma for patients and physicians alike. Failure to treat may subject the patient to personal suffering, deterioration, and loss of function, and can eventuate in death [3,4,5,13,15,59,60,61,62,63,64,65,66] (Supplementary File 1, 2a and 2b). Open-ended antimicrobial treatment is costly, requires medical oversight for safety, entails risks—including the risk of death—and theoretically risks the emergence of resistant strains of microbes, with public health implications [67,68].
In another peer-reviewed article, by Alain Trautmann, et. al., titled, Potential Patient-Reported Toxicities With Disulfiram Treatment in Late Disseminated Lyme Disease, it is reported that there are, “…severe and persistent toxic events in a patients suffering from a late disseminated form of Lyme Disease following disulfiram intake.” The article goes on to conclude that, “Thirteen out of 16 patients reported toxic events, and seven out of 16 reported benefits for at least part of their symptoms. Based on the collected observations, it seems too early to promote disulfiram as a promising new treatment until the reasons underlying the reported toxicities have been explored, and the results of a well-conducted double blind clinical trial published.”
The need for a truly effective and non-toxic treatment must be developed, and as you will read, has been developed.
New Development, INPT, Yields Encouraging Results
A new treatment concept, Induced Native Phage Therapy (INPT), has shown exciting clinical results as well as establishing laboratory verification of its effectiveness. Bacteriophages, or phages, are well researched, yet INPT is a completely new application of the science and appears to work by stimulating specific phages to swarm the target bacteria and completely eliminate even the difficult to reach bacteria that are coated with biofilms, and the pleomorphic forms called “persistor cells.” INPT is not to be compared to or thought of as any other previous use of bacteriophages, due to the fact that no bacteriophages are being introduced into the body from outside sources, but instead INPT is thought to stimulate native bacteriophage that already exist in the person with Lyme Borrelia.
Preliminary and ongoing testing has resulted in never before seen results, that appear to provide a viable solution of complete elimination of the Borrelia with minimal to no adverse side-effects or Herxheimer reactions, and no risk of creating resistant strains of microbes.
Results after One Week of INPT Treatment
Twelve people who were previously diagnosed with treatment-resistant, recurrent Lyme disease, underwent 24 total blood tests using the new highly sensitive lab test, Phelix Borrelia-Phage Test. Each person underwent two tests, one test prior to beginning INPT treatment initially tested to confirm each patient did indeed still have Borrelia sp. infection, in spite of previous prolonged pharmaceutical and natural antimicrobial treatment, prior to being treated with INPT for one week. After one week of the discontinuation of the INPT treatment, the test was repeated to confirm all Borrelia were eliminated. All twelve patients who previously tested positive, were found to be negative on the followup Phelix Borrelia-Phage Test, as well as being found to also be negative on conventional Borrelia PCR testing, which was used to doubly confirm the findings. These results appear to demonstrate that this novel treatment, INPT:
- Completely eradicates the Borrelia, Borrelia-persistor cells
- Rapid eradication of all Borrelia, usually less than seven days
- Has no known adverse effects
- Causes minimal Herxheimer reactions
- Only affects the targeted type of bacteria, leaving friendly flora unaffected
- Can be targeted to address any of the different strains of Borrelia sp.
- Is designed to penetrate bacterial biofilms
- Crosses the blood-brain-barrier
- Being a complex frequency-based oral remedy it is completely non-toxic and non-allergenic
- Does not require a healthy immune system
To date, many patients have undergone treatment with INPT, with over 60 Phelix Borrelia-Phage Tests being performed in total, the results of which are yet to be determined. Clinical cure, as in the quote above from Dr. Liegner, is a difficult issue to determine, since the eradication of the causative bacteria, while wonderful, does not repair the damage of having the infection for months, years, or even decades in some cases. However, the majority of patients have experienced more rapid and often more dramatic symptom-relief that would be expected with the disappearance of the offending bacteria, Borrelia. Symptom improvement has varied from each individual, with the most dramatic being a few individuals who were wheelchair bound due to their prolonged battle with the infection have been able to stand up from the wheelchair and in one case is able to walk.
Ongoing testing is underway to continue to document the long-term elimination of the Borrelia in these patients. No other treatments for Borrelia were used with the INPT, nor have any of the patients needed re-treatment for Borrelia in the months following their one week of INPT.
The attraction of this work is obvious, however it is even more exciting when considering that if verified with continued INPT treatment and phage testing, the reality is that when there are no Borrelia bacteria or persistor cells left, a person will not be not in remission, as seen with conventional antibiotic treatment when symptoms abate for a period, but because a few bacteria remain in spite of prolonged antibiotic treatment, their illness may return. With none of the Borrelia left in the body, there is no remission, as the person is cured. Reinfection would require the person to acquire the infection by one of the many transmitting vectors, such as ticks.
With the laboratory confirmation of elimination of Borrelia, it appears that a person can now begin and end treatment of Borrelia within an unheard of two week period.
It must be reiterated that Lyme disease is much like having termites damaging the wood of your house. While killing all of the termites (Lyme microbes) is definitely a good thing, the killing of the bugs does nothing to repair the damage they caused in the wood of your house (your body). The first stiff wind will still stress or knock your house down. Instant resolution of all of a person’s symptoms is virtually impossible, even when all of the infection is gone, unless you were only recently infected and only minimal damage has been done to your body. The damage must be addressed in its entirety, in those people with chronic infection and many or severe symptoms.
To continue the house analogy, a hammer will not cut wood, although you cannot build and repair a house without one. In the same manner, an antibiotic or even INPT treatment that eliminates the bacteria is a tool that also just serves its purpose, but cannot repair damaged systems and tissues. One must have many healing tools in the toolbox, and the skill to use those tools, in order to restore optimum health once more.
INPT Does Not Cause a Major Herxheimer – Worsening of Symptoms
The delivery of the INPT treatment has been well-tolerated, even by people who are sensitive to almost all medicines, making it ideal for those with MCS, MCAS, and other hypersensitivity conditions.
The way phages kill a microbe causes much less “die-off” worsening of a person’s symptoms than antibiotics and other antimicrobial products. We now know from research that a “Herx” reaction is not actually from the bacterial guts (endotoxins) spilling into the body as the bacteria are killed as with antibiotics. A Herx reaction is due to the proinflammatory cytokines released by the body’s immune cells that engulfed the dying bacteria. With phage killing of the bacteria the bacteria explodes where it sits and only the debris is cleaned up by the immune cells. The debris does not cause much of a proinflammatory cytokine release and therefore the best treatment outcome is possible, faster and complete annihilation of the target microbe, with less worsening of the patient’s symptoms.
Ongoing Development of INPT at the Biologix Center
INPT was developed and is being used at the Biologix Center for Optimum Health to target any microbial issue, including all of the co-infections associated with Lyme disease, as well as Candida sp., mold, and parasite infections, however the only phage lab test available at this time is for Borrelia strains.
If you would like to participate in our two week INPT program please contact us at www.biologixcenter.com/get-treatment/. Financial assistance is available for those with chronic illness of any type, who desire treatment at Biologix Center and are struggling financially.
A more detailed report of these findings are presently being edited for publication in peer-reviewed article submission.
Bartonella Research Collaboration
The Biologix Center is collaborating with researchers who are working to develop phage lab tests for Bartonella and other types of microbes. The Phelix Bartonella-Phage Test is hoped to be offered before the end of 2020. If you have been diagnosed with Bartonella and would like to contribute a blood sample for the development of this new test, please let us know. Offer available only to patients of the Biologix Center who have been pre-qualified by our testing.
To learn more about Bacteriophages and INPT please click on the hyperlink.
*INPT is an innovation developed by Dr. David A. Jernigan, D.N.M, D.C., the founder and CEO of the Biologix Center for Optimum Health, in Franklin, Tennessee. An Retrospective Registry IRB is in place to publish peer-reviewed articles as this clinical work progresses.